TIME TO NORMALIZATION OF SERUM TESTOSTERONE AFTER 3-MONTH LUTEINIZING HORMONE-RELEASING HORMONE AGONIST ADMINISTERED IN THE NEOADJUVANT SETTING: IMPLICATIONS FOR DOSING SCHEDULE AND NEOADJUVANT STUDY CONSIDERATION
The DOI matches its Crossref record.
Abstract
PURPOSE: A time course to serum testosterone normalization after administration of a single 3-month luteinizing hormone-releasing hormone (LH-RH) agonist in the neoadjuvant setting was developed. MATERIALS AND METHODS: A total of 13 men with clinically localized prostate cancer were prospectively assessed for baseline libido, erectile function and mid morning serum testosterone. A single 3-month formulation LH-RH agonist was administered in the neoadjuvant setting before definitive treatment with radical perineal prostatectomy in 7 men or external beam radiotherapy in 6. Baseline and serial testosterone levels were measured 3, 4, 6, 7, 9, 12, 15 and 18 months after injection. Symptoms related to acute testosterone depletion, namely hot flashes and sweats, were recorded on the same schedule. RESULTS: After a single 3-month LH-RH agonist injection median duration of castrate level testosterone (0.2 ng./ml. or less) was 6 months. Median duration of hypogonadal symptoms (hot flashes and sweats) was 13.6 months and resolution paralleled the gradual return of serum testosterone to baseline values. CONCLUSIONS: The 3-month formulation of LH-RH agonist administered in the neoadjuvant setting provides castrate level testosterone for a longer duration than the product labeling suggests. If confirmed, these preliminary observations have important implications for dosing schedule and neoadjuvant study consideration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2497 · Cited by 1,455
D'Amico, A. V., Denham, J. W., Crook, J., Chen, M.-H., Goldhaber, S. Z., Lamb, D. S., Joseph, D., Tai, K.-H., Malone, S., Ludgate, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.3369 · Cited by 501
Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer
Knudsen, K. E., & Penning, T. M. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.01.002 · Cited by 293
QUALITY OF LIFE OUTCOMES AFTER BRACHYTHERAPY FOR EARLY STAGE PROSTATE CANCER
BRANDEIS, J. M., LITWIN, M. S., BURNISON, C. M., & REITER, R. E. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)67818-4 · Cited by 188
Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated?
SCOLIERI, M. J., ALTMAN, A., & RESNICK, M. I. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)67008-5 · Cited by 68
Metadata
- Authors
- OEFELEIN, M. G.
- Venue
- Journal of Urology
- Published
- 1998-11
- Volume
- 160
- Issue
- 5
- Pages
- 1685-1688
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2025053238
- Cited by
- 103
- References
- 0
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TIME TO NORMALIZATION OF SERUM TESTOSTERONE AFTER 3-MONTH LUTEINIZING HORMONE-RELEASING HORMONE AGONIST ADMINISTERED IN THE NEOADJUVANT SETTING: IMPLICATIONS FOR DOSING SCHEDULE AND NEOADJUVANT STUDY CONSIDERATION. https://app.cochat.ai/papers/10.1016/s0022-5347(01)62383-8
- The paper
- OEFELEIN, M. G. (1998). TIME TO NORMALIZATION OF SERUM TESTOSTERONE AFTER 3-MONTH LUTEINIZING HORMONE-RELEASING HORMONE AGONIST ADMINISTERED IN THE NEOADJUVANT SETTING: IMPLICATIONS FOR DOSING SCHEDULE AND NEOADJUVANT STUDY CONSIDERATION. Journal of Urology. https://doi.org/10.1016/s0022-5347(01)62383-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.